Biohaven Ltd. (NYSE:BHVN) presented early clinical data for its experimental cancer drug BHV-1510 showing high response rates when combined with an immunotherapy agent, according to a company statement released Thursday. The clinical-stage biopharmaceutical company, currently valued at $1.41 billion, has seen its stock gain 10.3% over the past week despite being down 75.2% over the past year.
The data, presented at the 2025 European Society for Medical Oncology Immuno-Oncology Congress in London, showed that patients receiving BHV-1510 with cemiplimab achieved a 72.7% confirmed objective response rate at the 2.5 mg/kg dose level.
The drug combination demonstrated particularly strong results in specific cancer types, with confirmed responses observed in 60% of non-small cell lung cancer patients, 100% of endometrial cancer patients, and 50% of urothelial cancer patients.
Most study participants had previously received multiple treatments, with 87.1% having prior exposure to PD-(L)1 immunotherapy agents. Despite this heavily pretreated population, the majority of participants showed tumor reduction on their first scan, with a median time to response of 11.1 weeks.
"The early responses we are observing in these difficult-to-treat tumors are particularly encouraging," said Dr. Ida Micaily, principal investigator and assistant professor at Sidney Kimmel Comprehensive Cancer Center at Jefferson, in the press release.
The company reported that BHV-1510 was generally well tolerated with low rates of common side effects associated with similar drugs, such as neutrophil count decrease (12.9%), diarrhea (6.5%), and alopecia (9.7%). No cases of interstitial lung disease were reported, and no participants discontinued treatment due to adverse events.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.